VcMMAE|646502-53-6|(MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE)-陌孚医药/Medlife

您当前的位置：

VcMMAE (Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE)

目录号: PL07242 纯度: ≥99%

CAS No. :646502-53-6

商品编号	规格	价格	会员价
PL07242-5mg	5mg	¥803.00	请登录
PL07242-10mg	10mg	¥1125.00	请登录
PL07242-50mg	50mg	¥3214.00	请登录
PL07242-100mg	100mg	¥4821.00	请登录
PL07242-200mg	200mg	询价	询价
PL07242-500mg	500mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	VcMMAE
中文别名	马来酰亚胺己酰基-缬氨酸-瓜氨酸-对氨基苄氧羰基单甲基奥瑞他汀E
英文名称	VcMMAE
英文别名	VcMMAE;MC-VC-PAB-MMAE;Val-cit-pab-mmae;Vc-MMAE;Maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl monomethylauristatin E;4147AH;C68H105N11O15;AK187613;MC-VC-PAB-MMAE,MC-Val-Cit-PAB-MMAE;A14362
Cas No.	646502-53-6
分子式	C₆₈H₁₀₅N₁₁O₁₅
分子量	1316.63
包装储存	-20°C, sealed storage, away from moisture and light 该产品在溶液状态不稳定，建议您现用现配，即刻使用。

产品详情	VcMMAE (mc-vc-PAB-MMAE) 是抗体偶联药物的一部分 (drug-linker conjugate for ADC)，具有抗癌活性，它由 MMAE (一种 tubulin 抑制剂) 和 valine-citrulline (vc) 连接而成。
生物活性	VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
性状	Solid
IC50 & Target[1][2]	Auristatin
体外研究(In Vitro)	Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30 cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	-20°C, sealed storage, away from moisture and light 该产品在溶液状态不稳定，建议您现用现配，即刻使用。
参考文献	[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.

溶解度数据	In Vitro: DMSO : ≥ 54 mg/mL (41.01 mM)H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation